Professor Peter van der Meer, MD, PhD
University Medical Center Groningen, Netherlands
Peter van der Meer is a cardiologist, chair of the Department of Experimental Cardiology and director of the Coronary Care Unit at University Medical Center Groningen. He is also a Professor of Heart Failure and Translational Cardiology at the University of Groningen.
Professor van der Meer received both his MD and PhD cum laude from the University of Groningen, and completed a postdoctoral fellowship at Harvard Medical School, Boston, MA, USA. He authored >300 manuscripts, has an H-index of 77 and was member of the 2022 ESC CardioOncology guidelines. He is a member of several steering committees of large phase 3 trials. His research is funded by national and international grants including an ERC StG and CoG grant. His research group consists of PhD students and post-docs with various backgrounds (biologists, medical doctors and biomedical-engineers) working on translational research topics to bridge the gap between bench and bedside. Professor van der Meer’s research focusses on understanding the susceptibility to develop heart failure and on exploring novel treatment targets and therapies.

Prof. Carlo Gabriele Tocchetti is currently Associate Professor of Medicine in the Department of Translational Medical Sciences, Federico II University, Naples, Italy since 2014, where he is Director of the Internal Medicine Unit for cancer patients and has established himself as a HF basic and clinical investigator. Prof Tocchetti is President, International Cardio-Oncology Society (ICOS) Italy Chapter, Fellow of the HFA, Chair of the Basic Science Section of the HFA, and Board member of the ESC Council on Cardio-Oncology.
The main goal of his lab is to explore pathophysiologic mechanisms and therapeutic targets in cardiac dysfunction, with a particular interest on post-ischemic HF, genetic and inflammatory cardiomyopathies, Pulmonary Hypertension and RV dysfunction, and HF due to antineoplastic therapies, including novel anticancer immunotherapies and biologic drugs employed in inflammatory diseases.

Thomas Suter is board-certified in cardiology and internal medicine and the head of the Department of Internal Medicine at Lindenhofgruppe in Bern, Switzerland. In addition, he leads the Cardio-Oncology Service and is a member of the section for heart failure and cardiac transplantation at the University Hospital Bern. He received his medical degree from the University of Zurich and took residency training in internal medicine and cardiology at University Hospital Zürich, Boston University Medical Center and Brigham and Women’s Hospital, Boston MA. During his cardiology training, he specialized on heart failure and cardiac transplantation. His clinical research during the past 20 years focused on the investigation of cardiovascular side effects of cancer therapeutics. He currently serves as the chair of the Council on Cardio-Oncology of the European Society of Cardiology and on several steering committees of multinational cancer trials. Furthermore, he is directing a basic research lab in which he investigates mechanisms of chemotherapeutic-associated cardiotoxicity. His publications include over 100 articles on heart failure, cancer drug-associated cardiovascular side effects and general cardiology and more than 20 books on general and internal medicine.
Selected publications:
Cardio-oncology in clinical studies and real life. Dent SF, Suter TM, Minotti G et al. Semin Oncol. 2019 Dec;46(6):421-425
Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab.
Lenihan D, Suter T, Baselga J et al. Ann Oncol. 2019 Jun 1;30(6):1021.
Modern-day cardio-oncology: a report from the 'Heart Failure and World Congress on Acute Heart Failure 2018'. Anker MS, Suter T, Lyon AR et al. Heart Failure Association Cardio-Oncology Study Group of the European Society of Cardiology. ESC Heart Fail. 2018 Dec;5(6):1083-1091
Cardio-Oncology Services: rationale, organization, and implementation.
Lancellotti P, Suter TM, Asteggiano R et al. Eur Heart J. 2019 Jun 7;40(22):1756-1763.
Cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge. Ameri P, Suter T, Tocchetti CG et al. Heart Failure Association Cardio-Oncology Study Group of the European Society of Cardiology. Eur J Heart Fail. 2018 May;20(5):879-887
Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06). Ponde N, Suter T, de Azambuja E et al. Breast Cancer Res Treat. 2018 Apr;168(3):631-638.
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. von Minckwitz G, Suter T, Baselga J et al. N Engl J Med. 2017 Jul 13;377(2):122-131.
Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy. Zardavas D, Suter TM, de Azambuja E et al. J Clin Oncol. 2017 Mar 10;35(8):878-884.
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Zamorano JL, Lancellotti P, Suter TM et al.; ESC Scientific Document Group. Eur Heart J. 2016 Sep 21;37(36):2768-2801.

Tienush Rassaf is Director and Chair of the Department of Cardiology and Vascular Medicine at the University Hospital Essen, Germany, and Vice-Dean of Research of the Medical Faculty in Essen. Prof Rassaf is an interventional cardiologist with a research focus on cardioprotection in acute myocardial infarction and myocardial ischemia/reperfusion- injury. He is founding member and has been chairmen of the working group ‘Cardiooncology’ of the German Cardiac Society (DGK). On of his current research interests focus on the prevention of cardiotoxicity.

Wouter C. Meijers MD PhD FESC FHFA (Experimental) Cardiology Department
Erasmus MC, Rotterdam, The Netherlands
Dr. Wouter C. Meijers obtained his medical degree at the Maastricht University. After which he was granted a PhD position at the (Experimental) cardiology department of prof. de Boer and prof. van Veldhuisen, which he later on defended cum laude. His translational studies focused on heart failure and more specifically on cardio-oncology. He pioneered on the reciprocal relationship between cancer and heart failure. Furthermore, he co-founded the more specialized field of cardio-immuno-oncology. He obtained several national and international grands and awards which helped him to pursue his research career. He was the first Dutch cardiologist in training whom performed a post-doctoral fellowship in the field of cardio-oncology at the Vanderbilt University Medical Center in Nashville, Tennessee, USA with prof. Moslehi. He is currently fellow of both the European Society of Cardiology as the Heart Failure Association. He recently transferred within the Netherlands to Rotterdam, the Erasmus Medical Center to further train himself within (advanced) heart failure and cardio-oncology and to further expand his own research group.

Teresa López-Fernández is a clinical investigator and senior consultant cardiologist at the University Hospital of La Paz in Madrid, Spain. Dr López-Fernández specialises in cardiac imaging and cardio-oncology. Dr López-Fernández coordinates the Cardio-Oncology Clinic at the University Hospital of La Paz. She is the founder and president of the Spanish Cardio-Oncology Working Group of the Spanish Society of Cardiology (SEC). She is also vice-president of the International Cardio-Oncology Society (ICOS) and was elected president of the ESC Council for Cardio-Oncology. Dr López-Fernández is co-chair of the ESC Guidelines on Cardio-Oncology 2022. Her current research interests focus on the diagnosis and prevention of cardiotoxicity.

Prof. Dimitrios Farmakis, MD, PhD, FESC, FHFA
National and Kapodistrian University of Athens Medical School, Athens University Hospital Attikon, Athens, Greece.
Prof. Farmakis main clinical and research focus is heart failure, cardio-oncology and haemoglobinopathy-associated cardiovascular disease. He has a strong publication record in highly-ranked journals (283 PubMed articles, total citations, 22124; h index, 65) and textbooks (72 chapters, 5 complete textbooks). He has received grants for research projects and has served as primary investigator or steering committee member in research programs funded by the European Commission. He also sits on editorial boards of international medical journals and on several scientific or advisory committees, while he serves as a reviewer for many highly-rated journals. Among others, he is the Chairman of the European Society of Cardiology (ESC) Heart Failure Association Study Group on Cardio-Oncology, President of the Hellenic Society of Cardiology Working Group on Oncocardiology and member of ESC guidelines taskforces on heart failure and cardio-oncology. He is also a medical advisor to Thalassaemia International Federation (TIF) and editor of the recent TIF guidelines for transfusion-dependent thalassaemia. He has received awards and distinctions from the Universities of Athens and Patras, Harvard Medical School, American Heart Association, United Arab Emirates government and others.